Inhibition of TCR/CD3‐mediated signaling by a mutant of the hematopoietically expressed G16 GTP‐binding protein

Jie Zhou,J. Stanners,P. Kabouridis,Hyunsil Han,C. Tsoukas

DOI: https://doi.org/10.1002/(SICI)1521-4141(199805)28:05<1645::AID-IMMU1645>3.0.CO;2-D

1998-05-01

European Journal of Immunology

Abstract:We have investigated the role of the hematopoietically expressed G16 GTP‐binding protein on T cell activation. We constructed transfectants of Jurkat T cells that express a function‐deficient mutant of Gα16 predicted to prevent activation of this G protein. Upon stimulation with anti‐CD3ϵ antibodies, mutant Gα16 transfectants display a profound defect in the production of IL‐2 and IL‐10, as well as in the expression of CD69. In contrast, the phorbol 12‐myristate 13‐acetate (PMA)‐induced IL‐10 production and CD69 expression, and the ionomycin plus PMA‐induced IL‐2 production are not affected. Consistent with the reduction in cytokine production is the inhibition of early signaling events in the mutant Gα16‐expressing cells. There are significant reductions in anti‐ϵ‐induced tyrosine phosphorylation of ζ, ϵ, ZAP‐70, and phospholipase Cγ1, as well as in intracellular Ca2+ mobilization. In accordance with the effects on tyrosine phosphorylation is the reduction of TCR/CD3‐mediated Fyn and Lck activities in Gα16 mutant cells. Even though the mechanism through which the Gα16 mutant mediates inhibition of T cell activation is not known, the data suggest a model where G proteins become activated upon TCR/CD3 engagement and regulate the activation of tyrosine kinases and subsequent downstream signaling events that lead to the activation of cytokine genes.